CN112566904A - 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法 - Google Patents

一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法 Download PDF

Info

Publication number
CN112566904A
CN112566904A CN201980052673.2A CN201980052673A CN112566904A CN 112566904 A CN112566904 A CN 112566904A CN 201980052673 A CN201980052673 A CN 201980052673A CN 112566904 A CN112566904 A CN 112566904A
Authority
CN
China
Prior art keywords
formula
compound
crystal form
solvent
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980052673.2A
Other languages
English (en)
Inventor
邱振均
张全良
韦艳丽
曹永兴
杨俊然
马亚辉
杜振兴
王捷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN112566904A publication Critical patent/CN112566904A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

提供一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法。具体而言，提供一种式(I)所示化合物的I晶型、II晶型、III晶型、IV晶型、V晶型及其制备方法。新晶型具备良好的稳定性，可更好地用于临床治疗。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201980052673.2A 2018-10-22 2019-10-21 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法 Pending CN112566904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811231321 2018-10-22
CN2018112313217 2018-10-22
PCT/CN2019/112216 WO2020083188A1 (zh) 2018-10-22 2019-10-21 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法

Publications (1)

Publication Number Publication Date
CN112566904A true CN112566904A (zh) 2021-03-26

Family

ID=70330660

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980052673.2A Pending CN112566904A (zh) 2018-10-22 2019-10-21 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法

Country Status (12)

Country Link
US (1) US20210355109A1 (zh)
EP (1) EP3872072A4 (zh)
JP (1) JP2022508864A (zh)
KR (1) KR20210081367A (zh)
CN (1) CN112566904A (zh)
AU (1) AU2019365166A1 (zh)
BR (1) BR112021007477A2 (zh)
CA (1) CA3115872A1 (zh)
MX (1) MX2021004600A (zh)
TW (2) TWI770934B (zh)
WO (1) WO2020083188A1 (zh)
ZA (1) ZA202103278B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202115027A (zh) * 2019-08-30 2021-04-16 大陸商江蘇恒瑞醫藥股份有限公司 低雜質含量的酪胺酸激酶抑制劑

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN107793399A (zh) * 2016-09-07 2018-03-13 上海翰森生物医药科技有限公司 Cdk4/6抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020639A (zh) 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN103539783A (zh) 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN105367552A (zh) * 2015-01-09 2016-03-02 苏州晶云药物科技有限公司 来那替尼马来酸盐的新晶型及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN107793399A (zh) * 2016-09-07 2018-03-13 上海翰森生物医药科技有限公司 Cdk4/6抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
TWI770934B (zh) 2022-07-11
TW202030186A (zh) 2020-08-16
BR112021007477A2 (pt) 2021-07-27
EP3872072A4 (en) 2022-07-13
MX2021004600A (es) 2021-06-15
KR20210081367A (ko) 2021-07-01
TWI762825B (zh) 2022-05-01
TW202130629A (zh) 2021-08-16
CA3115872A1 (en) 2020-04-30
WO2020083188A1 (zh) 2020-04-30
US20210355109A1 (en) 2021-11-18
EP3872072A1 (en) 2021-09-01
ZA202103278B (en) 2022-08-31
AU2019365166A1 (en) 2021-06-03
JP2022508864A (ja) 2022-01-19

Similar Documents

Publication Publication Date Title
CN113527203B (zh) 乐伐替尼甲磺酸盐的晶型及其制备方法和用途
CA2984724C (en) Crystal of uracil compound
RU2672563C1 (ru) Кристаллы 3,5-дизамещенного бензолалкинильного соединения
CN110746403A (zh) 地匹福林盐酸盐的稳定型晶体及其结晶化方法
CN114746412A (zh) Kd-025的新晶型及其制备方法
KR20170032330A (ko) Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도
US11352368B2 (en) Salt of fused ring pyrimidine compound, crystal form thereof and preparation method therefor and use thereof
CN108779122B (zh) 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
CN112566904A (zh) 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法
CN111108098B (zh) 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
CN109516991A (zh) 一种枸橼酸托法替尼晶型化合物及其制备方法
CN115433246A (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
EP4230625A1 (en) Crystal form of multi-substituted benzene ring compound maleate, and preparation method therefor and use thereof
CN110240562B (zh) 一种脯氨酰羟化酶抑制剂的可药用盐、晶型及其制备方法
CN111138414A (zh) 一种酪氨酸激酶抑制剂的晶型及其制备方法
CN112174895B (zh) 一种雄性激素受体抑制剂的晶型及其制备方法
CN109384791B (zh) 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
WO2019029477A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法
CN116283919A (zh) Vimseltinib的新晶型及其制备方法
CN116063291A (zh) 一种杂环化合物马来酸盐的晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050155

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210326